Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.
Identifieur interne : 000180 ( Main/Exploration ); précédent : 000179; suivant : 000181Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.
Auteurs : Weijie Qiang [République populaire de Chine] ; Yifei Dai [République populaire de Chine] ; Guibo Sun [République populaire de Chine] ; Xiaoyan Xing [République populaire de Chine] ; Xiaobo Sun [République populaire de Chine]Source :
- Annals of translational medicine [ 2305-5839 ] ; 2020.
Abstract
Background
Colon adenocarcinoma (COAD) is one of the most commonly diagnosed cancers, and it is closely related to the immune microenvironment. Considering that immunotherapy is not effective for all COAD patients, it is necessary to identify the effective population before administering treatment. In this study, we established an independent prognostic index based on immune-related genes (IRGs), in order to evaluate the clinical outcome of COAD.
Methods
The gene expression profiles and IRGs taken from The Cancer Genome Atlas (TCGA) and Immunology Database and Analysis Portal (ImmPort), respectively, were integrated in order to identify the differentially expressed IRGs. Functional enrichment analysis was conducted and the prognostic value of survival-related IRGs was determined. Based on Cox regression analysis, the IRG-based prognostic index (IRGPI) was established, and the model was evaluated and applied.
Results
A total of 51 differentially expressed survival-related IRGs were identified. The most significant signaling pathway was "cytokine-cytokine receptor interaction". The index established herein was based on 12 survival-related IRGs, and it was highly accurate in monitoring prognosis. Moreover, the IRGPI was significantly correlated with multiple clinicopathologic factors, as well as with the infiltration of immune cells.
Conclusions
An independent IRGPI was established in order to assess the immune status and tumor prognosis in COAD patients. This index can serve as a robust biomarker in clinical prognosis applications, including cancer immunotherapy.
DOI: 10.21037/atm.2020.03.09
PubMed: 32355728
PubMed Central: PMC7186653
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.</title><author><name sortKey="Qiang, Weijie" sort="Qiang, Weijie" uniqKey="Qiang W" first="Weijie" last="Qiang">Weijie Qiang</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Dai, Yifei" sort="Dai, Yifei" uniqKey="Dai Y" first="Yifei" last="Dai">Yifei Dai</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine, Tsinghua University, Beijing 100084, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Medicine, Tsinghua University, Beijing 100084</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Sun, Guibo" sort="Sun, Guibo" uniqKey="Sun G" first="Guibo" last="Sun">Guibo Sun</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Xing, Xiaoyan" sort="Xing, Xiaoyan" uniqKey="Xing X" first="Xiaoyan" last="Xing">Xiaoyan Xing</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Sun, Xiaobo" sort="Sun, Xiaobo" uniqKey="Sun X" first="Xiaobo" last="Sun">Xiaobo Sun</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32355728</idno><idno type="pmid">32355728</idno><idno type="doi">10.21037/atm.2020.03.09</idno><idno type="pmc">PMC7186653</idno><idno type="wicri:Area/Main/Corpus">000145</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000145</idno><idno type="wicri:Area/Main/Curation">000145</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000145</idno><idno type="wicri:Area/Main/Exploration">000145</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.</title><author><name sortKey="Qiang, Weijie" sort="Qiang, Weijie" uniqKey="Qiang W" first="Weijie" last="Qiang">Weijie Qiang</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Dai, Yifei" sort="Dai, Yifei" uniqKey="Dai Y" first="Yifei" last="Dai">Yifei Dai</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine, Tsinghua University, Beijing 100084, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Medicine, Tsinghua University, Beijing 100084</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Sun, Guibo" sort="Sun, Guibo" uniqKey="Sun G" first="Guibo" last="Sun">Guibo Sun</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Xing, Xiaoyan" sort="Xing, Xiaoyan" uniqKey="Xing X" first="Xiaoyan" last="Xing">Xiaoyan Xing</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Sun, Xiaobo" sort="Sun, Xiaobo" uniqKey="Sun X" first="Xiaobo" last="Sun">Xiaobo Sun</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author></analytic><series><title level="j">Annals of translational medicine</title><idno type="ISSN">2305-5839</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>Background</b></p><p>Colon adenocarcinoma (COAD) is one of the most commonly diagnosed cancers, and it is closely related to the immune microenvironment. Considering that immunotherapy is not effective for all COAD patients, it is necessary to identify the effective population before administering treatment. In this study, we established an independent prognostic index based on immune-related genes (IRGs), in order to evaluate the clinical outcome of COAD.</p></div><div type="abstract" xml:lang="en"><p><b>Methods</b></p><p>The gene expression profiles and IRGs taken from The Cancer Genome Atlas (TCGA) and Immunology Database and Analysis Portal (ImmPort), respectively, were integrated in order to identify the differentially expressed IRGs. Functional enrichment analysis was conducted and the prognostic value of survival-related IRGs was determined. Based on Cox regression analysis, the IRG-based prognostic index (IRGPI) was established, and the model was evaluated and applied.</p></div><div type="abstract" xml:lang="en"><p><b>Results</b></p><p>A total of 51 differentially expressed survival-related IRGs were identified. The most significant signaling pathway was "cytokine-cytokine receptor interaction". The index established herein was based on 12 survival-related IRGs, and it was highly accurate in monitoring prognosis. Moreover, the IRGPI was significantly correlated with multiple clinicopathologic factors, as well as with the infiltration of immune cells.</p></div><div type="abstract" xml:lang="en"><p><b>Conclusions</b></p><p>An independent IRGPI was established in order to assess the immune status and tumor prognosis in COAD patients. This index can serve as a robust biomarker in clinical prognosis applications, including cancer immunotherapy.</p></div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32355728</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2305-5839</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of translational medicine</Title><ISOAbbreviation>Ann Transl Med</ISOAbbreviation></Journal><ArticleTitle>Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.</ArticleTitle><Pagination><MedlinePgn>284</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/atm.2020.03.09</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">Colon adenocarcinoma (COAD) is one of the most commonly diagnosed cancers, and it is closely related to the immune microenvironment. Considering that immunotherapy is not effective for all COAD patients, it is necessary to identify the effective population before administering treatment. In this study, we established an independent prognostic index based on immune-related genes (IRGs), in order to evaluate the clinical outcome of COAD.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">The gene expression profiles and IRGs taken from The Cancer Genome Atlas (TCGA) and Immunology Database and Analysis Portal (ImmPort), respectively, were integrated in order to identify the differentially expressed IRGs. Functional enrichment analysis was conducted and the prognostic value of survival-related IRGs was determined. Based on Cox regression analysis, the IRG-based prognostic index (IRGPI) was established, and the model was evaluated and applied.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 51 differentially expressed survival-related IRGs were identified. The most significant signaling pathway was "cytokine-cytokine receptor interaction". The index established herein was based on 12 survival-related IRGs, and it was highly accurate in monitoring prognosis. Moreover, the IRGPI was significantly correlated with multiple clinicopathologic factors, as well as with the infiltration of immune cells.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">An independent IRGPI was established in order to assess the immune status and tumor prognosis in COAD patients. This index can serve as a robust biomarker in clinical prognosis applications, including cancer immunotherapy.</AbstractText><CopyrightInformation>2020 Annals of Translational Medicine. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiang</LastName><ForeName>Weijie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Guibo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaobo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Ann Transl Med</MedlineTA><NlmUniqueID>101617978</NlmUniqueID><ISSNLinking>2305-5839</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colon adenocarcinoma (COAD)</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">immune-related genes (IRGs)</Keyword><Keyword MajorTopicYN="N">prognostic index</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32355728</ArticleId><ArticleId IdType="doi">10.21037/atm.2020.03.09</ArticleId><ArticleId IdType="pii">atm-08-06-284</ArticleId><ArticleId IdType="pmc">PMC7186653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Methods Mol Biol. 2016;1418:111-41</Citation><ArticleIdList><ArticleId IdType="pubmed">27008012</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2015 Jun 1;33(16):1787-96</Citation><ArticleIdList><ArticleId IdType="pubmed">25918287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2009;4(1):44-57</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2013 Mar 10;31(8):1039-49</Citation><ArticleIdList><ArticleId IdType="pubmed">23401433</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2017 May;18(5):573-582</Citation><ArticleIdList><ArticleId IdType="pubmed">28288100</ArticleId></ArticleIdList></Reference><Reference><Citation>Theranostics. 2017 Aug 22;7(14):3585-3594</Citation><ArticleIdList><ArticleId IdType="pubmed">28912897</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2017;1446:221-229</Citation><ArticleIdList><ArticleId IdType="pubmed">27812946</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncotarget. 2017 Apr 18;8(16):27252-27262</Citation><ArticleIdList><ArticleId IdType="pubmed">28460478</ArticleId></ArticleIdList></Reference><Reference><Citation>J Surg Res. 2008 Jan;144(1):29-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17950328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Carcinog. 2017 Nov;56(11):2512-2526</Citation><ArticleIdList><ArticleId IdType="pubmed">28667784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2008 Jan 15;24(2):282-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18006545</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2017 Nov 1;77(21):e108-e110</Citation><ArticleIdList><ArticleId IdType="pubmed">29092952</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Dec 11;9:2909</Citation><ArticleIdList><ArticleId IdType="pubmed">30619273</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2020 Mar;235(3):2037-2048</Citation><ArticleIdList><ArticleId IdType="pubmed">31612481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2019 Jun 1;35(11):1968-1970</Citation><ArticleIdList><ArticleId IdType="pubmed">30395168</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2017 Jul 27;130(4):453-459</Citation><ArticleIdList><ArticleId IdType="pubmed">28600341</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncotarget. 2017 Sep 23;8(50):87837-87847</Citation><ArticleIdList><ArticleId IdType="pubmed">29152124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Transl Med. 2018 Apr;6(7):121</Citation><ArticleIdList><ArticleId IdType="pubmed">29955581</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncol Rep. 2018 May;39(5):2365-2375</Citation><ArticleIdList><ArticleId IdType="pubmed">29565464</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2015 Apr 20;43(7):e47</Citation><ArticleIdList><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>CA Cancer J Clin. 2016 Jan-Feb;66(1):75-88</Citation><ArticleIdList><ArticleId IdType="pubmed">26528881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2017 Nov 2;13(11):2575-2582</Citation><ArticleIdList><ArticleId IdType="pubmed">28362548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2017 Dec;232(12):3468-3480</Citation><ArticleIdList><ArticleId IdType="pubmed">28098359</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2018 May;19(5):497-507</Citation><ArticleIdList><ArticleId IdType="pubmed">29662170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361</Citation><ArticleIdList><ArticleId IdType="pubmed">27899662</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2017 Aug;22(8):1224-1232</Citation><ArticleIdList><ArticleId IdType="pubmed">28545838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2016 Sep 15;32(18):2847-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2017 Apr 7;17(1):53</Citation><ArticleIdList><ArticleId IdType="pubmed">28388943</ArticleId></ArticleIdList></Reference><Reference><Citation>CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e79</Citation><ArticleIdList><ArticleId IdType="pubmed">24132163</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2017 Jan 14;68:139-152</Citation><ArticleIdList><ArticleId IdType="pubmed">27860544</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncoimmunology. 2017 Apr 20;6(6):e1319027</Citation><ArticleIdList><ArticleId IdType="pubmed">28680752</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discov. 2012 May;2(5):401-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22588877</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2019 Mar;18(3):197-218</Citation><ArticleIdList><ArticleId IdType="pubmed">30610226</ArticleId></ArticleIdList></Reference><Reference><Citation>Anticancer Res. 2014 Jan;34(1):423-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24403498</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Res. 2014 May;58(2-3):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24791905</ArticleId></ArticleIdList></Reference><Reference><Citation>PeerJ. 2018 Jun 14;6:e4942</Citation><ArticleIdList><ArticleId IdType="pubmed">29915691</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2016 Jan 21;374(3):211-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26789870</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2015 Jan 1;75(1):5-10</Citation><ArticleIdList><ArticleId IdType="pubmed">25524899</ArticleId></ArticleIdList></Reference><Reference><Citation>CA Cancer J Clin. 2018 Nov;68(6):394-424</Citation><ArticleIdList><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2011 Nov 15;71(22):6940-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21940749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2013 Oct;14(10):1014-22</Citation><ArticleIdList><ArticleId IdType="pubmed">24048123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country><settlement><li>Pékin</li></settlement></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Qiang, Weijie" sort="Qiang, Weijie" uniqKey="Qiang W" first="Weijie" last="Qiang">Weijie Qiang</name></noRegion><name sortKey="Dai, Yifei" sort="Dai, Yifei" uniqKey="Dai Y" first="Yifei" last="Dai">Yifei Dai</name><name sortKey="Qiang, Weijie" sort="Qiang, Weijie" uniqKey="Qiang W" first="Weijie" last="Qiang">Weijie Qiang</name><name sortKey="Sun, Guibo" sort="Sun, Guibo" uniqKey="Sun G" first="Guibo" last="Sun">Guibo Sun</name><name sortKey="Sun, Guibo" sort="Sun, Guibo" uniqKey="Sun G" first="Guibo" last="Sun">Guibo Sun</name><name sortKey="Sun, Xiaobo" sort="Sun, Xiaobo" uniqKey="Sun X" first="Xiaobo" last="Sun">Xiaobo Sun</name><name sortKey="Sun, Xiaobo" sort="Sun, Xiaobo" uniqKey="Sun X" first="Xiaobo" last="Sun">Xiaobo Sun</name><name sortKey="Xing, Xiaoyan" sort="Xing, Xiaoyan" uniqKey="Xing X" first="Xiaoyan" last="Xing">Xiaoyan Xing</name><name sortKey="Xing, Xiaoyan" sort="Xing, Xiaoyan" uniqKey="Xing X" first="Xiaoyan" last="Xing">Xiaoyan Xing</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000180 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000180 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32355728
|texte= Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32355728" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |